Pfizer Files Lawsuit Against Novo: Alleges Competitor Engaged in Antitrust Scheme to Dominate Obesity Market
- Pfizer sues Novo Nordisk and Metsera in Delaware courts, alleging anticompetitive tactics to block its $7.2B obesity drug acquisition. - Novo's $8.5B superior bid for Metsera's GLP-1 pipeline—valued at $5B peak sales—triggers legal claims over regulatory bypass and contract violations. - Pfizer leverages early FTC approval for its deal, seeking court orders to force a November 13 shareholder vote amid patent expiration threats. - The dispute highlights $150B obesity market stakes, with Novo defending its
Pfizer Inc. (PFE) has intensified its legal efforts to maintain its stake in the obesity-focused biotech company
The dispute revolves around Metsera’s pipeline of experimental GLP-1 treatments, which feature a once-monthly injectable that has demonstrated an average 14% weight reduction in clinical trials, as well as a chemically stabilized oral version. Analysts estimate these products could achieve peak annual sales of $5 billion, according to
Pfizer’s legal argument is based on its regulatory advantage: the FTC ended its Hart-Scott-Rodino review early on October 31, ahead of the November 7 deadline, as noted by
This legal showdown highlights the growing rivalry in the obesity medication industry, which analysts expect to reach $150 billion in value by 2030. Novo, facing increased competition from Eli Lilly’s tirzepatide, is working to strengthen its drug portfolio before semaglutide patents expire. Meanwhile, Pfizer is attempting to gain entry into the sector after discontinuing its oral obesity drug candidate, danuglipron, as reported by
Metsera’s investors, led by Population Health Partners and ARCH Venture Partners, are under investigation for possible collusion with Novo, according to
With Pfizer facing a November 5 deadline to respond to Novo’s proposal and a shareholder vote approaching, Delaware courts are poised to decide whether competitive issues or contractual commitments will take precedence in this major pharmaceutical dispute.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana News Update: Mutuum Finance's DeFi Strategy: Balancing Stability Against Shiba Inu's Fluctuations
- Mutuum Finance (MUTM) raises $18.27M in presale with 80% completion, targeting $0.06 launch price for 400% potential gains. - Project combines Solana's utility-driven growth with SHIB's viral appeal via dual-lending model and automated risk management protocols. - CertiK audit (90/100) and $50K bug bounty address DeFi security risks, while buy-and-distribute mechanism boosts token value retention. - Whale investments and structured tokenomics (45.5% presale allocation) signal institutional confidence ahe
Bitcoin News Update: Retail Investors Panic While Institutions Accumulate as Bitcoin Challenges $106K Support Level
- Bitcoin fell below $100,000 on October 30, 2025, its first drop in six months amid heightened volatility. - ETF outflows ($488M) and institutional buying (397 BTC at $114,771) highlight retail caution vs. institutional confidence. - Analysts warn of 65%-70% drawdown risks over two years, citing weak investor understanding and panic selling cycles. - Regulatory shifts (e.g., Wyoming stablecoin plans) offer partial support but fail to offset year-to-date price swings ($67k-$124k). - Market uncertainty pers
Ethereum News Update: BullZilla Soars by 2,381%, Outperforming ETH and PEPE Amid October Decline
- BullZilla ($BZIL) surged 2,381% in October 2025, defying market downturns with deflationary tokenomics and a 24-stage presale model. - Ethereum (ETH) and Pepe (PEPE) declined 2.45% and 5.92% respectively amid broader "October Clearance Sale" corrections. - BullZilla's structured approach, including staking rewards and token burns, attracted $1M in presale funds and 3,300+ holders. - Analysts highlight BullZilla's measurable performance and transparent design as key differentiators in the competitive meme
Genius Sports Sees Revenue Growth Despite Lower Profits; Analysts Maintain $15 Price Target
- Genius Sports (GENI) reports Q3 2025 earnings with $156.27M revenue but -$0.18 EPS, showing revenue growth vs. worsening losses. - Analysts maintain "Outperform" rating (avg. $15 target, 33% upside) despite GF Value model suggesting $10.45 fair value. - Stock faces pressure from profitability challenges, with June 2025 post-earnings drop highlighting revenue-profitability disconnect.
Trending news
MoreCrypto prices
More
